SEC Filing Summary: RXi Pharmaceuticals Corporation (Form 8-K)
Business Context and Reporting Period
RXi Pharmaceuticals Corporation (also referenced as Phio Pharmaceuticals Corp. in metadata) filed a Current Report on Form 8-K on May 13, 2015. The filing announces the results of operations for the quarter ended March 31, 2015. The company is incorporated in Delaware with principal executive offices in Marlborough, Massachusetts.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification that these results were reported and directs readers to Exhibit 99.1 (the Press Release) for the detailed financial data.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for comparative analysis.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 will not be treated as "filed" under Section 18 of the Securities Exchange Act of 1934 and will not be incorporated by reference into other filings unless expressly stated. No specific guidance, outlook, or risk factors are detailed in the text of the 8-K itself.
Key Facts for Investor Verification
- Verify the specific financial results (revenue, net loss, cash position) in the Press Release dated May 13, 2015 (Exhibit 99.1), as they are not listed in the 8-K body.
- Confirm the company's current name status, as the metadata lists "Phio Pharmaceuticals Corp." while the filing header lists "RXi Pharmaceuticals Corporation."
- Note that Geert Cauwenbergh serves as President, CEO, and acting CFO.
- Review the press release for any forward-looking statements or operational updates not captured in this summary notification.